The Trump administration is considering a controversial plan to create a Domestic Civil Disturbance Quick Reaction Force, deploying hundreds of National Guard troops to cities facing unrest. This initiative has significant implications for civil-military relations and public safety.
With the federal government stepping in, Terry Cole leads the charge to tackle crime in Washington, D.C. Discover his extensive background and the implications of this unprecedented move.
The Trump administration's decision to allow Nvidia to export a scaled-down AI chip to China raises serious concerns about U.S. technology supremacy. Critics warn that this could enable China to leapfrog America in AI capabilities.
The Trump administration's recent attempts to disclose information about Jeffrey Epstein and Ghislaine Maxwell have been labeled a smokescreen by a judge, raising questions about transparency and accountability.
In a stunning decision, a federal judge has rejected the Trump administration's bid to unseal grand jury testimony related to Ghislaine Maxwell and Jeffrey Epstein, criticizing the government's motives and claiming the documents lack new information.
In a significant ruling, a federal judge denied the Trump administration's request to release grand jury transcripts related to Ghislaine Maxwell, debunking claims of new insights into Epstein's crimes. This decision comes amid rising public outrage and conspiracy theories surrounding Epstein's death.
A decade after declaring the Monroe Doctrine dead, the U.S. faces backlash as Trump orders military action against drug cartels in Latin America, raising fears of renewed interventions.
The Trump administration is reportedly planning an IPO for the Great American Mortgage Corporation, aiming to raise $30 billion. Analysts express skepticism about the timeline and execution, emphasizing the need for government support to maintain mortgage rates.
In a stunning twist, IRS Commissioner Billy Long has been dismissed just two months into his term after a clash over taxpayer data and immigration. Discover the reasons behind this historic removal and its implications.
Dr. Vinay Prasad is back at the FDA's Center for Biologics Evaluation and Research, raising eyebrows after being ousted amid political turmoil and criticism. His return ignites debates about drug approvals and public health leadership under the Trump administration.
